apposters.com
Edit

NFLS - Pivotal

https://www.pivotalbiovp.com
Last activity: 06.05.2026
Active
Invests in categories: BioTechDrugPlatformDevelopmentMedtechPharmaceuticalsImmunologyArtificial IntelligenceTechnologyTherapeutics
Portfolio
19
Mentions
9
Investment Type: Venture Capital
Investment Stage: Series B

Portfolio 19

DateNameWebsiteTotal RaisedLocation
26.04.2023Evommuneevommune.com$405.5MUnited Sta...
18.11.2022Lucy Thera...lucytherapeutics.com$12.5MUnited Sta...
05.11.2022ARKUDA The...arkudatx.com$108MUnited Sta...
05.11.2022HotSpot Th...hotspotthera.com$210MUnited Sta...
-SutroVaxsutrovax.com$281MUnited Sta...
-Vigil Neur...vigilneuro.com$255MUnited Sta...
-Fusion Pha...fusionpharma.com$195.91MCanada, On...
-Plexiumplexium.com$225MUnited Sta...
-Oculis S.A...oculis.com$704.2MSwitzerlan...
-Akouosakouos.com$162.5MUnited Sta...
Show more

Mentions in press and media 9

DateTitleDescription
06.05.2026Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology PipelineWindward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S...
07.05.2021Oculis closes US$57 million Series C financingThe oversubscribed round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Cap...
07.05.2021Oculis closes US$57 million Series C financing
05.01.2018Oculis raises CHF20 million and moves to Switzerland
04.01.2018Oculis Raises $20.3M Series B from Novartis Venture FundOculis (www.oculis.com), a clinical-stage biotechnology company focused on the development of breakthrough non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing round of CHF 2...
21.05.2017Domain Associates Joins $65M Series B for IterumIterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, today announced that it has clo...
21.05.2017Iterum Raises $65M Series BIterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, today announced that it has clo...
16.03.2017Pivotal bioVenture Partners Closes $300M First Life Sciences FundSan Francisco, CA-based venture capital firm Pivotal bioVenture Partners closed its first fund, at over $300m. Funded by Hong Kong based Nan Fung Group, Pivotal bioVenture Partners Fund I aims to invest in early stage biotechnology companie...
-Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investo...

Reviews 0

Sign up to leave a review

Sign up Log In